MediWound (MDWD)

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Osakkeen MediWound Ltd. Ordinary Shares (MDWD) hinta tänään on eli muutosta on ollut epäluku % siitä, kun markkina avattiin. Yrityksen markkina-arvo on 220,89 milj. $, ja päivittäisen kaupankäynnin määrä on  osaketta. Edellinen sulkemishinta oli .

Aloitetaanko? Seuraa alla olevia vaiheita tai lue oppaamme siitä, miten ostaa MediWound osakkeita Krakenista alkaen 10 dollarista.